Silence Therapeutics PLC
SLN6.450USD
+0.080+1.26%
Close 12/22, 16:00（ET）Quotes delayed by 15 min
304.66MMarket Cap
LossP/E TTM
More Details of Silence Therapeutics PLC Company
Silence Therapeutics plc is a global clinical-stage biotechnology company engaged in transforming people’s lives by silencing diseases through precision-engineered medicines created with proprietary siRNA (short interfering RNA) technology. The Company leverages its mRNAi GOLD platform to create siRNAs designed to precisely target and silence disease-associated genes in the liver. The Company focuses on areas of high unmet medical need with programs advancing cardiovascular disease, hematology and rare diseases. Divesiran (SLN124) is its wholly owned siRNA product candidate designed to inhibit TMPRSS6 expression in the liver. Zerlasiran is a siRNA molecule designed for the treatment of cardiovascular disease associated with elevated Lp(a), a lipoprotein in the blood. In addition to its wholly owned clinical pipeline, it has a third siRNA product candidate from its mRNAi GOLD platform in Phase I development in an undisclosed indication through its collaboration with AstraZeneca.
Silence Therapeutics PLC Info
Ticker SymbolSLN
Company nameSilence Therapeutics PLC
IPO dateJan 05, 2010
CEOTooman (Craig A)
Number of employees116
Security typeDepository Receipt
Fiscal year-endJan 05
Address72 Hammersmith Road
CityLONDON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited Kingdom
Postal codeW14 8TH
Phone442034576900
Websitehttps://www.silence-therapeutics.com/
Ticker SymbolSLN
IPO dateJan 05, 2010
CEOTooman (Craig A)
Company Executives of Silence Therapeutics PLC
Name
Name/Position
Position
Shareholding
Change
Mr. Timothy (Tim) McInerney
Mr. Timothy (Tim) McInerney
Independent Director
Independent Director
--
--
Mr. Craig A. Tooman
Mr. Craig A. Tooman
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
--
--
Dr. Steven J. Romano, M.D.
Dr. Steven J. Romano, M.D.
Executive Vice President, Chief of Research and Development Officer
Executive Vice President, Chief of Research and Development Officer
--
--
Ms. Rhonda Heliums
Ms. Rhonda Heliums
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Mr. Iain Gladstone Ross
Mr. Iain Gladstone Ross
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. David Jakob (Dave) Lemus, CPA
Mr. David Jakob (Dave) Lemus, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Gem Hopkins
Ms. Gem Hopkins
Head of IR and Corporate Communications
Head of IR and Corporate Communications
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Timothy (Tim) McInerney
Mr. Timothy (Tim) McInerney
Independent Director
Independent Director
--
--
Mr. Craig A. Tooman
Mr. Craig A. Tooman
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
--
--
Dr. Steven J. Romano, M.D.
Dr. Steven J. Romano, M.D.
Executive Vice President, Chief of Research and Development Officer
Executive Vice President, Chief of Research and Development Officer
--
--
Ms. Rhonda Heliums
Ms. Rhonda Heliums
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Mr. Iain Gladstone Ross
Mr. Iain Gladstone Ross
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. David Jakob (Dave) Lemus, CPA
Mr. David Jakob (Dave) Lemus, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2024
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q3
FY2023Q2
FY2023Q1
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United Kingdom
43.11M
99.67%
Germany
144.00K
0.33%
USA
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Griffiths (Richard Ian)
24.38%
TCG Crossover Management, LLC
6.42%
Invus Public Equities Advisors, LLC
6.16%
Redmile Group, LLC
4.58%
Lombard Odier Asset Management (USA) Corp.
3.91%
Other
54.55%
Shareholders
Shareholders
Proportion
Griffiths (Richard Ian)
24.38%
TCG Crossover Management, LLC
6.42%
Invus Public Equities Advisors, LLC
6.16%
Redmile Group, LLC
4.58%
Lombard Odier Asset Management (USA) Corp.
3.91%
Other
54.55%
Shareholder Types
Shareholders
Proportion
Individual Investor
24.38%
Investment Advisor
18.46%
Investment Advisor/Hedge Fund
9.97%
Venture Capital
3.35%
Hedge Fund
3.30%
Research Firm
3.11%
Private Equity
2.05%
Bank and Trust
0.03%
Other
35.34%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
138
19.95M
42.23%
-14.76M
2025Q2
131
33.68M
71.31%
-14.18M
2025Q1
133
31.94M
67.63%
-14.00M
2024Q4
128
31.43M
66.56%
-10.23M
2024Q3
111
35.93M
77.05%
-5.19M
2024Q2
96
34.94M
74.95%
-4.57M
2024Q1
86
35.43M
76.18%
+4.14M
2023Q4
61
30.21M
78.15%
-609.51K
2023Q3
58
32.62M
88.08%
+1.55M
2023Q2
54
31.78M
89.08%
+2.79M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Griffiths (Richard Ian)
11.51M
24.38%
+543.58K
+4.95%
Jun 25, 2025
TCG Crossover Management, LLC
3.03M
6.42%
--
--
Jun 30, 2025
Invus Public Equities Advisors, LLC
2.91M
6.16%
+121.61K
+4.36%
Jun 30, 2025
Redmile Group, LLC
2.16M
4.58%
-50.17K
-2.27%
Jun 30, 2025
Lombard Odier Asset Management (USA) Corp.
1.85M
3.92%
--
--
Jun 30, 2025
Morgan Stanley & Co. LLC
1.13M
2.39%
-766.91K
-40.44%
Jun 30, 2025
Vivo Capital, LLC
1.11M
2.34%
--
--
Jun 30, 2025
Nantahala Capital Management, LLC
1.04M
2.21%
--
--
Jun 30, 2025
Frazier Life Sciences Management, L.P.
970.13K
2.05%
-178.46K
-15.54%
Jun 30, 2025
Nextech Invest, Ltd.
952.40K
2.02%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
Virtus LifeSci Biotech Clinical Trials ETF
0.87%
ProShares Ultra Nasdaq Biotechnology
0.03%
Invesco Nasdaq Biotechnology ETF
0.03%
SPDR S&P International Small Cap ETF
0.01%
ActivePassive International Equity ETF
0%
iShares Biotechnology ETF
0%
Tema Heart & Health ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.87%
ProShares Ultra Nasdaq Biotechnology
Proportion0.03%
Invesco Nasdaq Biotechnology ETF
Proportion0.03%
SPDR S&P International Small Cap ETF
Proportion0.01%
ActivePassive International Equity ETF
Proportion0%
iShares Biotechnology ETF
Proportion0%
Tema Heart & Health ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Silence Therapeutics PLC?
The top five shareholders of Silence Therapeutics PLC are:
Griffiths (Richard Ian) holds 11.51M shares, accounting for 24.38% of the total shares.
TCG Crossover Management, LLC holds 3.03M shares, accounting for 6.42% of the total shares.
Invus Public Equities Advisors, LLC holds 2.91M shares, accounting for 6.16% of the total shares.
Redmile Group, LLC holds 2.16M shares, accounting for 4.58% of the total shares.
Lombard Odier Asset Management (USA) Corp. holds 1.85M shares, accounting for 3.92% of the total shares.
Griffiths (Richard Ian) holds 11.51M shares, accounting for 24.38% of the total shares.
TCG Crossover Management, LLC holds 3.03M shares, accounting for 6.42% of the total shares.
Invus Public Equities Advisors, LLC holds 2.91M shares, accounting for 6.16% of the total shares.
Redmile Group, LLC holds 2.16M shares, accounting for 4.58% of the total shares.
Lombard Odier Asset Management (USA) Corp. holds 1.85M shares, accounting for 3.92% of the total shares.
What are the top three shareholder types of Silence Therapeutics PLC?
The top three shareholder types of Silence Therapeutics PLC are:
Griffiths (Richard Ian)
TCG Crossover Management, LLC
Invus Public Equities Advisors, LLC
Griffiths (Richard Ian)
TCG Crossover Management, LLC
Invus Public Equities Advisors, LLC
How many institutions hold shares of Silence Therapeutics PLC (SLN)?
As of 2025Q3, 138 institutions hold shares of Silence Therapeutics PLC, with a combined market value of approximately 19.95M, accounting for 42.23% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -29.08%.
What is the biggest source of revenue for Silence Therapeutics PLC?
In FY2024, the -- business generated the highest revenue for Silence Therapeutics PLC, amounting to -- and accounting for --% of total revenue.
